Selected aspirin treated patients may exhibit high platelet reactivity to agonists other than arachidonic acid. This study aimed to determine whether the VerifyNow™ identifies generalized high platelet reactivity supported by correlations with other established methods that stimulate platelets with various agonists. Stable outpatients with coronary artery disease (n = 110) were treated with aspirin in a two 3 x 3 Latin square design (81, 162 and 325 mg/day for 4 weeks each). VerifyNow™ (arachidonic acid (AA) cartridge); light transmittance aggregometry; thrombelastography; PFA-100®; flow cytometry; PlateletWorks®; and urinary 11- dehydro thromboxane levels were measured. Multianalyte profiling measured fibrinogen and von Willebrand factor (vWF). Patients with ≥550 ARU by VerifyNow™ had increased 5 mM AA-, 5 μM ADP-, and 2 μg/mL collagen-induced platelet aggregation compared to patients with <550 ARU (p ≤ 0.001). The highest ADP- and collagen-induced aggregation was present in the upper quartile by VerifyNow™ (p < 0.05). Fibrinogen or vWF levels did not differ between VerifyNow™ quartiles. Patients with high platelet reactivity to arachidonic acid identified by VerifyNow™ also exhibit increased reactivity to other important platelet agonists that is independent of fibrinogen and vWF levels. These data suggest that VerifyNow™ may identify a generalized high platelet reactivity phenotype.
- Platelet reactivity
ASJC Scopus subject areas